排序方式: 共有34条查询结果,搜索用时 13 毫秒
1.
目的研究氟尿嘧啶植入剂与蛋白变性剂6 mol·L-1盐酸的相容性,了解两者能否联用。方法装有氟尿嘧啶植入剂和盐酸试管96只置(37±0.5)℃下保温,于不同时间点各取6只试管内药粒,显微镜观察形态;高效液相色谱和紫外法测定氟尿嘧啶在盐酸中稳定性,紫外法测定药含量和饱和浓度;计算体外释放度,并与大鼠体内释放度比较。结果在(37±0.5)℃盐酸中,氟尿嘧啶960 h稳定,饱和质量浓度为(22.72±0.04)g·L-1,植入剂药粒完整,表面多孔,释药速率与大鼠体内相比,前期大,后期小,药物难以放完;1,96,360,960 h时释放度分别为(11.9±5.3)%,(52.6±4.3)%,(75.3±3.8)%,(85.3±2.1)%。结论氟尿嘧啶在(37±0.5)℃盐酸中略溶,960 h稳定,氟尿嘧啶植入剂在蛋白质变性剂6 mol·L-1盐酸中缓释药物,两者相容性好,可以联用。 相似文献
2.
3.
4.
5.
超声监测不孕症卵泡发育和子宫内膜厚度及治疗后的变化与受孕的关系 总被引:2,自引:0,他引:2
为了对女性不孕症患者进行无创性诊断及药物疗效的观察,近年来我们利用B型超声对28例不孕症妇女进行了64个排卵周期-药物诱导排卵周期36个和自然排卵周期28个卵泡生长发育和子宫内膜厚度及其治疗后改变进行了动态监测,分析其与受孕的关系。1材料和方法1.1选择月经周期规律(2~35d),丈夫精液正常的不孕症妇女28例.其中原发不孕25例,继发不孕3例,年龄26~38岁,排除生殖系统器质性病变。通过超声显像进行受孕周期或连续几个周期的围排卵期卵泡及子宫内膜监测,共监测64个周期,根据是否给予促排卵药分为M组。A组14例,为自然排卵周… 相似文献
6.
彩色多普勒超声对糖尿病患者肾脏大小与肾血流动力学关系的分析 总被引:3,自引:0,他引:3
目的:应用彩色多普勒超声观察对糖尿病患者肾脏大小形态、结构及各级肾动脉阻力指数(RI)的改变,分析肾脏大小与阻力指数之间的关系,以期寻找更早期的、无创性的糖尿病肾病(DN)辅助诊断方法.方法:选择120例糖尿病(DM)患者,病程<5年为DM1组60例,病程>5年为DM2组60例,排除合并心衰、泌尿系感染、结石、肾血管疾病及其他原因致肾脏原发、继发病变,所有患者尿常规蛋白阴性,血尿素氮、肌酐正常.同时选择120例健康者作为对照组.应用彩色多普勒超声仪检查受试者肾脏大小、各级肾动脉阻力指数.应用SPSS统计软件包进行统计处理.结果:DN2组糖尿病患者肾脏较正常对照组及DM1组者大,两者比较有统计学意义.DM2组RI较DM1组及正常组高.DM2组肾脏大小与肾各级动脉RI之间有线性关系,呈正相关(r=0.85,P<0.05).结论:彩色多普勒超声(CDFI)检测能提示DM患者肾脏大小和肾血流动力学情况,对早期DN的诊断是有价值的. 相似文献
8.
超声诊断子宫内膜间质肉瘤1例 总被引:1,自引:1,他引:0
患者女 ,2 9岁。阴道不规则出血伴头晕、乏力半年余 ,经期逐渐延长 ,且经量增多 ,在当地对症治疗未见好转 ,近日加重 ,来我院就诊。超声显示子宫明显增大 ,约 12 .0cm× 8.5cm× 10 .0cm ,表面尚光滑 ,实质回声不均匀 ,于宫体后壁可测及大小约 8.6cm× 6 .2cm× 6 .5cm之实质性偏低回声区 ,被膜欠清晰 ,与宫壁间分界不清 ,内部回声不均匀 ,并见极小的不规则透声区 ,子宫内膜线不清晰 (图 1)。双侧卵巢大小、形态、回声、结构正常。超声诊断 :巨大子宫肌瘤伴变性 (恶变 ?)。建议尽快手术。次日行诊刮 :宫腔 11.0cm ,内膜厚 ,凸… 相似文献
9.
目的探讨关节超声在痛风关节炎急性发作期的诊断价值。方法选取2017年1月至2017年12月急性痛风性关节炎患者30例为实验组,同期选取30例急性非痛风性关节炎患者为对照组,两组患者均采用关节超声检查。比较两组患者的超声表现特点,观察双轨征阳性患者的不同关节区域超声表现。结果实验组患者的双轨征、关节内或周围结节超声表现例数多于对照组,差异有统计学意义(P <0. 05);在所有扫查项目中,实验组与对照组患者关节内或关节周围结节、双轨征超声影像数据比较,差异有统计学意义(P <0. 05)。足趾关节与膝关节发生双轨征的阳性率高于其他部位,差异有统计学意义(P <0. 05)。结论关节超声在痛风关节炎急性发作期诊断中的应用效果显著,能够有效鉴别患者的疾病状况,尤其是借助双轨征可以准确判断患者是否属于痛风关节炎,其中膝关节与足趾关节属于重点筛查区域。 相似文献
10.
BACKGROUND: Directly percutaneous injection of protein-denaturant hydrochloric acid (PDHA) into tumors can lead to fast killing of tumor, sustained drug release and prevention of in situ recurrence of tumor. However, whether implants can be used combined with denaturant still remains unknown.
OBJECTIVE: To investigate the compatibility of fluorouracil implants and PDHA (6 mol/L).
DESIGN, TIME AND SETTING: Observational study was performed in the Hefei Industry University between October 2006 and March 2007.
MATERIALS: A total of 78 Wistar rats, weighing (200±20) g, half males and half females, were used for testing drug release in vivo. Drugs fluorouracil implants (H20030345; columniform particle, diameter 0.8 mm, length 4 mm; specifications: Fluorouracil 2 mg/particle; batch number: 20060922; meeting the National Drug Quality Standards [WS1-(X-103)-2005Z]) were provided by Wuhu Zhongren Pharmaceutical Company,Ltd. Hydrochloric acid (37%) was analytical reagent.
METHODS: 96 tubes of the implants and PDHA were kept at (37.0±0.5) ℃. Each time, six samples were collected at 1, 8, 16, 24, 96, 120, 168, 240, 360, 432, 480, 528, 600, 720, and 960 hours after incubation. Appearance of the implants was observed by microscope. Stability of fluorouracil in PDHA was determined by HPLC and ultraviolet absorb method. Based on the entering quantity and residual quantity of fluorouracil, the release rates were calculated.
MAIN OUTCOME MEASURES: The approximate solubility, stability and morphological change of fluorouracil in denaturant and the corresponding drug release character in both denaturant and rats in vivo.
RESULTS: At (37.0±0.5) ℃, the fluorouracil was stable for 960 hours in PDHA, the saturated concentration of fluorouracil was (22.72±0.04) g/L. The appearance of implants was intact. The surface was porous. Compared with the speed of releasing drug in rats, the speed of releasing drug was faster in the early stage of release process and slower in the later stage. The drug release was incomplete. At 1, 24, 96, 360 and 960 hours, the implants’ release rates were (11.9±6.7)%, (37.9±5.3)%, (52.6±4.5)%, (75.3±3.8)%, and (85.5±2.1)%, respectively.
CONCLUSION: The fluorouracil implants and hydrochloric acid (6 mol/L) are compatible and no influence is detected during the observation. 相似文献